Climb Bio announced positive topline data showing robust B-cell depletion from its budoprutug subcutaneous formulation in healthy volunteers, supporting continued development. Budoprutug, an anti-CD19 monoclonal antibody, is being tested in clinical trials for primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE), with initial data expected throughout 2026. The drug has received Fast Track Designation for pMN and is being developed in both intravenous and subcutaneous forms to maximize patient access. Climb Bio highlights budoprutug's potential to provide durable disease control by targeting a broad range of B cells, including those not addressed by current therapies.
BlackRock, Inc. has reported that its direct and indirect ownership in Orion Oyj has dropped below the 5% threshold as of June 15, 2026. This change requires a formal disclosure under Finnish securities law. The reduction in BlackRock's stake may aff...
On June 15, 2026, BlackRock, Inc. and its funds reduced their total holdings in Orion Corporation to below 5% of the company's shares and voting rights. This change was disclosed under the Finnish Securities Market Act, indicating a decrease from a p...
US stock futures showed mixed results with the S&P 500 slightly down while the Dow Jones and Nasdaq 100 edged higher following a recent rally. The market reacted to a preliminary US-Iran agreement aimed at extending a ceasefire and reopening the Stra...
MindWalk Holdings Corp. emphasizes the importance of a connected, trustworthy biological data layer over AI model size in drug discovery. The company launched ReefIQ™, a biological context layer, and LensAI™, a reasoning platform, aiming to reduce co...
Space Exploration Technologies Corp. (SpaceX) saw its shares surge over 11% in premarket trading, pushing its market capitalization close to $3 trillion, surpassing Amazon to become the fifth-largest company globally. This rapid valuation increase ha...
